EMD Serono Research & Development Institute, Inc.

This study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …

This Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This phase 2 trial tested a combination of two targeted drugs, tepotinib and osimertinib, in 140 people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and had stopped responding to the standard drug osimertinib. The goal was to see…

This early-phase trial tested a new drug called M6223, which blocks a protein called TIGIT that can turn off immune cells. M6223 was given alone or together with another drug, bintrafusp alfa, to 58 people with advanced solid tumors that had stopped responding to standard treatme…

This study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main g…

This completed study looked at how well cladribine tablets work in everyday practice for people with relapsing multiple sclerosis (MS) who had a poor response to other oral or infusion treatments. Researchers tracked 291 participants over 24 months, measuring relapse rates and pa…

This study tested an experimental drug called enpatoran in 456 people with lupus, a chronic autoimmune disease. Participants took either a low, medium, or high dose of enpatoran or a placebo for 24 weeks. The goal was to see if the drug safely reduces skin and overall disease act…

This study tested whether a new liquid form of follitropin alfa (a hormone used for fertility) works the same as the standard powder form. Fifty-five healthy men with low testosterone levels were given both versions at different times. The goal was to compare how the drug is abso…